来源: Pharmaceutical Technology
The FDA Office of Generic Drugs reported 956 generic drug approvals in 2023. Credit: FG Trade via Getty Images
The US Food and Drug Administration (FDA) Office of Generic Drugs has reported improvements in the number of generic drugs approved in its 2023 Annual Report, and detailed deficiencies that applicants needed to resolve before an approval could be made. Alongside this, the agency highlighted several actions that were made to fulfil its bid to improve generic medicine access.
The recent report highlighted that the FDA approved 956 generic drugs and issued 1,493 complete response letters last year, an improvement on 2022’s 914 approvals and 1,775 complete response letters.
来源: Pharmaceutical Technology
Moderna reports net loss of $4.7bn for full year 2023 来源: Pharmaceutical Technology
In recent years, the FDA has made larger efforts to encourage the development of generic medicines. In 2023, the organisation gave approximately $20m to fund science and research projects. It also expanded the responsibilities of the Generic Drug User Fee Act (GDUFA)-funded Center for Research on Complex Generics (CRCG) to improve research collaborations between the FDA, academic institutions, and the generic industry. In the same year, the FDA’s Office of Generic Drugs (OGD) also issued 12 policy documents to aid drug manufacturers in the development of generic drugs.
As of this year, the agency has continued with these developments, announcing its partnership with the European Medicines Agency (EMA) on 8 February. The two organisations have expanded the 2005 collaborative parallel scientific advice (PSA) programme, which gave sponsors a direct route to discuss scientific matters related to product development with regulators. The regulators extended the programme, allowing sponsors to continue engaging with regulators earlier in the development process. In the 22 February report, OGD director Dr Lilun Murphy said: “OGD will continue to focus on matters such as operational modernisation, workforce excellence, communication through conferences and education, direct engagement with companies developing generic drugs, and the meeting of our overall GDUFA programme goals.”